Waters Registers Acquity UPLC TQD as Medical Device with Chinese FDA | GenomeWeb

NEW YORK (GenomeWeb News) – Waters said today that the Chinese Food and Drug Administration has approved registration of its Acquity UPLC TQD system for sale as a medical device for routine diagnostic applications and neonatal metabolites disease screening.

The device is the second of Waters to receive Chinese approval for in vitro diagnostic applications. In 2008, the CFDA approved a neonatal screening test on the company's Quattro micro mass spec.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.